Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 18/20 | 0.63 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.55 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24616735 | 1.00 | KISS1R (0.63) | KISS1RNPFFR1IL23R | |
| SCHEMBL24616733 | 0.99 | KISS1R (0.62) | KISS1RNPFFR1IL23R | |
| SCHEMBL29517511 | 0.96 | KISS1R (0.58) | KISS1RNPFFR1IL23R | |
| SCHEMBL13166794 | 0.91 | KISS1R (0.63) | KISS1RIL23R | |
| SCHEMBL13166795 | 0.91 | KISS1R (0.63) | KISS1RIL23R | |
| SCHEMBL13166803 | 0.88 | IL23R (0.62) | KISS1RIL23R | |
| SCHEMBL13166804 | 0.88 | KISS1R (0.61) | KISS1RIL23R | |
| SCHEMBL31406959 | 0.87 | IL23R (0.62) | KISS1RIL23R | |
| SCHEMBL30044926 | 0.86 | RXFP1 (0.60) | KISS1RIL23R | |
| SCHEMBL29975121 | 0.86 | KISS1R (0.63) | KISS1RIL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220155-A1 | VASCULAR CHOLESTEROL INHIBITORS AND USE THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2022-07-14 | — | — | US | claimed |
| EP-3966234-A1 | VASCULAR CHOLESTEROL INHIBITORS AND USE THEREOF | Consejo Superior De Investigaciones Científicas (ES) | 2022-03-16 | — | — | EP | claimed |
| US-20220220155-A1 | VASCULAR CHOLESTEROL INHIBITORS AND USE THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2022-07-14 | — | — | US | disclosed |
| EP-3966234-A1 | VASCULAR CHOLESTEROL INHIBITORS AND USE THEREOF | Consejo Superior De Investigaciones Científicas (ES) | 2022-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220155-A1 | VASCULAR CHOLESTEROL INHIBITORS AND USE THEREOF | LDLR, APOB, HDLBP | KISS1R 1320/4885NPFFR1 1246/4885IL23R 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.